• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact
  • Show SearchSearch

Leflunomide (Arava®)

January 1, 2022

Selected References:

  • Arava Prescribing Information. Available online at http://products.sanofi.us/arava/arava.html [accessed Dec 2015].
  • Bérard A, et al. 2018. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis, 77(4):500-509.
  • Brent RL. 2001. Teratogen update: Reproductive risks of leflunomide (Arava); A pyrimidine synthesis inhibitor: Counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology, 63:106-112.
  • Briggs G, et al. 2015. Leflunomide. Drugs in Pregnancy and Lactation, A reference Guide to Fetal and Neonatal Risk, 10th edition (pp 781—784). Philadelphia, PA: Wolters Kluwer Health.
  • Cassina M, et al. 2012. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum, 64 (7):2085-94.
  • Chakravarty EF, et al. 2003. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol, 30:241-246.
  • Chambers CD, et al. 2010. Birth outcomes in pregnant women taking leflunomide. Arthritis Rheu, 62(5):1494-1503.
  • Chambers CD, et al. 2007. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Motherisk Update, 53(3):409-412.
  • De Santis M, et al. 2005. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis, 64:1096-1097.
  • Henson LJ, et al. 2020. Pregnancy outcomes in patients treated with lefunomide, the parent compound of the multiple sclerosis drug teriflunomide. Reprod Toxicol, 95:45-50.
  • Levy RA, et al. 2016. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev, 15(10):955-963.
  • Schaefer C, et al. 2015. Immunosuppression, rheumatic diseases, multiple sclerosis, and Wilson’s disease: Leflunomide. In: Drugs during pregnancy and lactation: Treatment options and risk assessment, 3rd ed (pp 362-363)(pp 658-659). London: Academic Press.
  • Viktil KK, et al. 2012. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol, 41(3):196-201.
  • Weber-Schoendorfer C, et al. 2017. Leflunomide – A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol. Aug;71:101-107.

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whooping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

Copyright © 2023 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^